Clinical Trial Update: TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating TILT-123, an oncolytic adenovirus encoding TNF-α and interleukin-2, used with tumor-infiltrating lymphocyte therapy for metastatic mela…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• TILT-123 (tilt-123)

Snippet

Sponsor: TILT Biotherapeutics Ltd. | Conditions: Metastatic Melanoma | Phase 1 | Status: COMPLETED